Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Literature DB >> 20046573

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Melarkode S Ramakrishnan¹, Anand Eswaraiah, Tania Crombet, Patricia Piedra, Giselle Saurez, Harish Iyer, A S Arvind.

Abstract

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This review focuses on the unique functional characteristics of nimotuzumab. Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN. Post marketing surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed. Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.

Entities: Chemical Disease Gene

Keywords: EGFR; SCCHN; glioma; humanized; monoclonal antibody; nimotuzumab; overall survival

Mesh：

Substances：

Year: 2009 PMID： 20046573 PMCID： PMC2715181 DOI： 10.4161/mabs.1.1.7509

Source DB: PubMed Journal: MAbs ISSN： 1942-0862 Impact factor: 5.857

17 in total

1. A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections.

Authors: A Fernandez; E Spitzer; R Perez; F D Boehmer; K Eckert; W Zschiesche; R Grosse
Journal: J Cell Biochem Date: 1992-06 Impact factor: 4.429

2. Nimotuzumab: evidence of clinical benefit without rash.

Authors: David G P Allan
Journal: Oncologist Date: 2005-10

3. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels.

Authors: T R Shockley; K Lin; C Sung; J A Nagy; R G Tompkins; R L Dedrick; H F Dvorak; M L Yarmush
Journal: Cancer Res Date: 1992-01-15 Impact factor: 12.701

Review 4. Recent developments related to the EGFR as a target for cancer chemotherapy.

Authors: Georgina Speake; Brian Holloway; Gerard Costello
Journal: Curr Opin Pharmacol Date: 2005-08 Impact factor: 5.547

Review 5. ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors: Nancy E Hynes; Heidi A Lane
Journal: Nat Rev Cancer Date: 2005-05 Impact factor: 60.716

6. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.

Authors: C Mateo; E Moreno; K Amour; J Lombardero; W Harris; R Pérez
Journal: Immunotechnology Date: 1997-03

7. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody.

Authors: Tania Crombet-Ramos; Janusz Rak; Rolando Pérez; Alicia Viloria-Petit
Journal: Int J Cancer Date: 2002-10-20 Impact factor: 7.396

8. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

Authors: Tania Crombet; Marta Osorio; Teresa Cruz; Carlos Roca; Ramón del Castillo; Rosa Mon; Normando Iznaga-Escobar; René Figueredo; James Koropatnick; Enrique Renginfo; Eduardo Fernández; Daniel Alvárez; Olga Torres; Mayra Ramos; Idrissa Leonard; Rolando Pérez; Agustín Lage
Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544

Review 9. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

Authors: Sufi Mary Thomas; Jennifer Rubin Grandis
Journal: Cancer Treat Rev Date: 2004-05 Impact factor: 12.111

Review 10. Incidence and management of cutaneous toxicities associated with cetuximab.

Authors: M Wasif Saif; Richard Kim
Journal: Expert Opin Drug Saf Date: 2007-03 Impact factor: 4.250

86 in total

1. Antibody-based therapeutics to watch in 2011.

Authors: Janice M Reichert
Journal: MAbs Date: 2011-01-01 Impact factor: 5.857

Review 2. Cancer stem cells: progress and challenges in lung cancer.

Authors: Amanda K Templeton; Shinya Miyamoto; Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal: Stem Cell Investig Date: 2014-04-15

Review 3. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.

Authors: Hyunbo Shim
Journal: Exp Mol Med Date: 2011-10-31 Impact factor: 8.718

4. Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells.

Authors: Arsham Banisadr; Yaghoub Safdari; Anvarsadat Kianmehr; Mahdieh Pourafshar
Journal: Hum Vaccin Immunother Date: 2017-12-21 Impact factor: 3.452

Review 5. Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.

Authors: Bhaskar Bhardwaj; Swaroop Revannasiddaiah; Himanshu Bhardwaj; Sree Balusu; Ali Shwaiki
Journal: Ann Transl Med Date: 2016-02

6. Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.

Authors: Abhinav Tiwari; Anson K Abraham; John M Harrold; Anup Zutshi; Pratap Singh
Journal: AAPS J Date: 2016-12-21 Impact factor: 4.009

7. Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.

Authors: Ting Jin; Yuan Zhu; Jia-Lin Luo; Ning Zhou; De-Chuan Li; Hai-Xin Ju; Yong-Tian Fan; Yong Liu; Yu-Ping Zhu; Hai-Yang Feng; Lu-Ying Liu
Journal: Int J Colorectal Dis Date: 2015-01-08 Impact factor: 2.571